Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients

作者: Jan Kulpa , Ewa Wójcik , Marian Reinfuss , Leszek Kołodziejski

DOI: 10.1093/CLINCHEM/48.11.1931

关键词:

摘要: Background: Carcinoembryonic antigen (CEA), squamous cell carcinoma (SCC-Ag), and CYFRA 21-1 are the most useful markers for non-small lung cancer (NSCLC), but neuron-specific enolase (NSE) is a tumor maker of choice SCLC. The determination NSE in NSCLC could allow selection patients with neuroendocrine features. whose tumors have properties may be more responsive to chemotherapy; however, these been reported aggressive. Tumor not suitable diagnosis; their principal applications monitoring therapy prognosis. Methods: were measured 200 untreated (SQC) reference group (n = 220; 124 healthy persons 96 nonmalignant disease). CEA SCC-Ag by microparticle enzyme immunoassays on Abbott AxSYM IMx analyzers. electrochemiluminescence Roche Elecsys 2010. Results: CEA, SCC-Ag, 21-1, increased above cutoffs 26%, 32%, 67%, 28% tested patients, respectively. area under ROC curve was higher than those (SQC vs controls). significantly advanced SQC early stages disease ( P <0.0001 <0.0004, respectively). In multivariate analysis survival, an independent nonspecific prognostic factor operable whereas disease. Conclusion: earlier SQC.

参考文章(26)
R. Moll, Cytokeratins in the histological diagnosis of malignant tumors. International Journal of Biological Markers. ,vol. 9, pp. 63- 69 ,(1994) , 10.1177/172460089400900201
Zofia Stasik, Jan Kulpa, Ewa Wojcik, Andrzej Radkowski, Leszek Kolodziejski, CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Research. ,vol. 20, pp. 5035- 5040 ,(2000)
Henri Pujol, Jean-Pierre Daurès, Jean-Louis Pujol, François-Bernard Michel, Jean Grenier, Alain Daver, Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer Cancer Research. ,vol. 53, pp. 61- 66 ,(1993)
Julio Sanchez De Cos, Fernando Masa, Jose L. de la Cruz, Carlos Disdier, Carmen Vergara, Squamous Cell Carcinoma Antigen (SCC Ag) in the Diagnosis and Prognosis of Lung Cancer Chest. ,vol. 105, pp. 773- 776 ,(1994) , 10.1378/CHEST.105.3.773
P. Weynants, Michel Symann, Yves Humblet, J L Canon, Biology of small cell lung cancer: an overview. European Respiratory Journal. ,vol. 3, pp. 699- 714 ,(1990)
S L Graziano, R Mazid, N Newman, A Tatum, A Oler, J A Mortimer, J J Gullo, S M DiFino, A J Scalzo, The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1398- 1406 ,(1989) , 10.1200/JCO.1989.7.10.1398
M Takada, N Masuda, E Matsuura, Y Kusunoki, K Matui, K Nakagawa, T Yana, I Tuyuguchi, I Oohata, M Fukuoka, Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. British Journal of Cancer. ,vol. 71, pp. 160- 165 ,(1995) , 10.1038/BJC.1995.33
Bengt Bergman, Fred-Thomas Brezicka, Carl-Peter Engström, Sture Larsson, Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer European Journal of Cancer. ,vol. 29, pp. 198- 202 ,(1993) , 10.1016/0959-8049(93)90174-E
V. Hespanhol, H. Queiroga, A. Magalhães, A.R. Santos, M. Coelho, A. Marques, Survival predictors in advanced non-small cell lung cancer Lung Cancer. ,vol. 13, pp. 253- 267 ,(1995) , 10.1016/0169-5002(95)00497-1